Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?

被引：14
作者：
Chin, Paul K. L. [1 ]
Vella-Brincat, Jane W. A. [1 ]
Barclay, Murray L. [1 ]
Begg, Evan J. [1 ]
机构：
[1] Christchurch Hosp, Dept Clin Pharmacol, Christchurch 8011, New Zealand
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2012年 / 74卷 / 05期
关键词：
THROMBIN INHIBITOR DABIGATRAN; VENOUS THROMBOEMBOLISM; ATRIAL-FIBRILLATION; PHARMACODYNAMICS; PHARMACOKINETICS; PREVENTION; ENOXAPARIN; REPLACEMENT; WARFARIN;
D O I：
10.1111/j.1365-2125.2012.04266.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：734 / 740
页数：7
相关论文
共 21 条
  • [1] Anon, 2011, PRADAXA 75 MG HARD C
  • [2] Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran
    Beasley, B. Nhi
    Unger, Ellis F.
    Temple, Robert
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1788 - 1790
  • [3] A unified pharmacokinetic approach to individualized drug dosing
    Begg, Evan J.
    Chin, Paul K. L.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (03) : 335 - 339
  • [4] The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    Blech, Stefan
    Ebner, Thomas
    Ludwig-Schwellinger, Eva
    Stangier, Joachim
    Roth, Willy
    [J]. DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) : 386 - 399
  • [5] Emergency Hospitalizations for Adverse Drug Events in Older Americans
    Budnitz, Daniel S.
    Lovegrove, Maribeth C.
    Shehab, Nadine
    Richards, Chesley L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (21) : 2002 - 2012
  • [6] A systematic review of the associations between dose regimens and medication compliance
    Claxton, AJ
    Cramer, J
    Pierce, C
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (08) : 1296 - 1310
  • [7] Newly Identified Events in the RE-LY Trial
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Yusuf, Salim
    Reilly, Paul A.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) : 1875 - 1876
  • [8] Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
    Eikelboom, John W.
    Wallentin, Lars
    Connolly, Stuart J.
    Ezekowitz, Mike
    Healey, Jeff S.
    Oldgren, Jonas
    Yang, Sean
    Alings, Marco
    Kaatz, Scott
    Hohnloser, Stefan H.
    Diener, Hans-Christoph
    Franzosi, Maria Grazia
    Huber, Kurt
    Reilly, Paul
    Varrone, Jeanne
    Yusuf, Salim
    [J]. CIRCULATION, 2011, 123 (21) : 2363 - U72
  • [9] Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial
    Eriksson, B. I.
    Dahl, O. E.
    Rosencher, N.
    Kurth, A. A.
    Van Dijk, N.
    Frostick, S. P.
    Kalebo, P.
    Christiansen, A. V.
    Hantel, S.
    Hettiarachchi, R.
    Schnee, J.
    Buller, H. R.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) : 2178 - 2185
  • [10] Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial
    Eriksson, Bengt I.
    Dahl, Ola E.
    Rosencher, Nadia
    Kurth, Andreas A.
    van Dijk, C. Niek
    Frostick, Simon P.
    Prins, Martin H.
    Hettiarachchi, Rohan
    Hantel, Stefan
    Schnee, Janet
    Bueller, Harry R.
    [J]. LANCET, 2007, 370 (9591) : 949 - 956
123